Johnson & Johnson Reports Significant Survival Benefit in Phase 3 Study of Carvykti for Multiple Myeloma Johnson & Johnson has […]

Boehringer Ingelheim and Gubra Launch Phase 1 Study of BI 3034701, a Promising Triple Agonist Peptide for Obesity Treatment Boehringer

AstraZeneca’s application for sipavibart has been accepted by the European Medicines Agency (EMA) through an accelerated assessment procedure. This application

WHO Issues Landmark Guideline to Boost Global Tobacco Cessation Efforts The World Health Organization (WHO) has released its inaugural guideline

Samsung Bioepis Receives FDA Approval for Pyzchiva, a Biosimilar to Stelara, for Multiple Inflammatory Conditions Samsung Bioepis Co., Ltd. has

The US Food and Drug Administration has granted approval for donanemab, a new treatment for Alzheimer’s disease developed by Eli

TauRx Pharmaceuticals Ltd, a global leader in Alzheimer’s disease research focusing on tau proteins, has applied for permission to sell

A federal judge has dealt a blow to a group of cancer victims aiming to block Johnson & Johnson’s proposed

Altimmune, a biotech company relatively unknown until now, is aiming to disrupt the weight loss medication market dominated by giants

Merck’s Capvaxive, the world’s first pneumococcal disease vaccine tailored for adults, has cleared a crucial hurdle in its challenge against